Ranked 15th in the Indian pharmaceutical industry MAT August, 2023 (source: Awacs).
Leader by Rx in Diabetes & Cardiology segments.
We are the leaders in the oral anti-diabetic segment in India in terms of both prescriptions and value. It is a position we have held consistently for almost two decades. In 2022-23, we crossed the milestone of Rs. 4,000 Crs.
We are also leaders in the cardiovascular disease segment in terms of prescription generation. In terms of value, we rank fourth.
Presence in Nutritional and Gynaecology segments through innovative products from partners in USA and Europe and in Cosmetology with a leading European brand.